Sub-Lingual Dexmedetomidine in Agitation Associated With Dementia

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-12-27

Study Completion Date

2022-01-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an adaptive Phase 1b/2 trial design. It is randomized, double-blind, placebo-controlled, multiple ascending dose study assessing efficacy, pharmacokinetics, safety and tolerability of BXCL-501 dosing in adult (65 years and older) males and females with acute agitation associated with dementia. Evaluation of 3 doses are planned.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY II)

NCT05271552

Agitation Dementia

COMPLETED PHASE3

Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III)

NCT05665088

Agitation Dementia

TERMINATED PHASE3

An Efficacy, and Safety Study Of BXCL501 For The Treatment Of Agitation Associated With Dementia

NCT05276830

Agitation Dementia

TERMINATED PHASE2

Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Participants With Alzheimer's Disease

NCT01584440

Agitation Alzheimer's Disease

COMPLETED PHASE2

Assessing Clinical Outcomes in Alzheimer's Disease Agitation

NCT04797715

Agitation in Patients With Dementia of the Alzheimer's Type Alzheimer Disease Agitation,Psychomotor

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a Phase 1b/2 randomized, double-blind, placebo controlled, ascending dose finding study assessing efficacy, pharmacokinetics, safety, and tolerability of BXCL501 with 3 dosing groups in adult (65 years and older) males and females with acute agitation associated with all forms of dementia. Evaluation of three (3) doses of sublingual BXCL 501 are planned. Cohort 1, Cohort 2 and Cohort 3 will be given 30µg, 60µg and 90µg dose respectively of BXCL501 or placebo. Subjects assigned to Cohort 3 will participate in a 1-week safety observation before being enrolled.

This is an adaptive design as doses selected for testing may be different from these, based upon safety reviews. Doses lower or higher may be chosen to test, up to 180µg, and additional subjects may be added to a cohort. BXCL501 films may be divided in half if needed to deliver half-dose strengths. At least 30 subjects (10 per cohort) will be enrolled at up to 3 study sites in the United States. In Part B a total of 46 subjects will receive BXCL501 40 μg or matching placebo film.

The effects of BXCL 501 on acute agitation will be assessed by the following scales: Pittsburgh Agitation Scale (PAS), the PANSS-EC (PEC), Cohen-Mansfield Agitation Inventory (CMAI), CGI-Severity for Agitation and CGI Improvement for Agitation. Adverse Events (AEs), clinical laboratory tests, ECG, and vital signs will be monitored, and all observed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Agitation,Psychomotor Dementia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) This is a double-blind study. Due to the nature of the drug, the pharmacist and the drug administrator will both be aware of the treatment. They have no other responsibility in the trial

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort 1- 30 Micrograms

Cohort 1 consists of 10 patients out of whom 8 patients receive 30 Micrograms film and the remaining 2 patients receive a placebo

Group Type ACTIVE_COMPARATOR

Sublingual film containing Dexmedetomidine

Intervention Type DRUG

Sublingual film containing Dexmedetomidine

Sublingual Placebo Film

Intervention Type DRUG

Sublingual placebo film that matches BXCL501

Cohort 2- 60 Micrograms

Cohort 2 consists of 10 patients out of whom 8 patients receive 60 Micrograms film and the remaining 2 patients receive a placebo.

Additional 20 subjects receive 60 Micrograms or placebo.

Group Type ACTIVE_COMPARATOR

Sublingual film containing Dexmedetomidine

Intervention Type DRUG

Sublingual film containing Dexmedetomidine

Sublingual Placebo Film

Intervention Type DRUG

Sublingual placebo film that matches BXCL501

Cohort 3- 90 Micrograms

Cohort 3 consists of 10 patients out of whom 8 patients receive 90 Micrograms film and the remaining 2 patients receive a placebo

Group Type ACTIVE_COMPARATOR

Sublingual film containing Dexmedetomidine

Intervention Type DRUG

Sublingual film containing Dexmedetomidine

Sublingual Placebo Film

Intervention Type DRUG

Sublingual placebo film that matches BXCL501

Part B Cohort

Part B cohort consists 46 subjects receiving 40 Micrograms or placebo

Group Type ACTIVE_COMPARATOR

Sublingual film containing Dexmedetomidine

Intervention Type DRUG

Sublingual film containing Dexmedetomidine

Sublingual Placebo Film

Intervention Type DRUG

Sublingual placebo film that matches BXCL501

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sublingual film containing Dexmedetomidine

Intervention Type DRUG

Sublingual Placebo Film

Sublingual placebo film that matches BXCL501

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

BXCL501

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and female patients 65 years and older.
* Patients who have dementia and a history of acute agitation.
* History of agitation that requires intervention or impairs social or daily activities
* Patients who meet International Psychogeriatric Association (IPA) diagnostic criterion for agitation.
* Patients with a total score of ≥ 8 on the Pittsburgh Agitation Scale (PAS).
* Patients who have a score of ≥ 2 on at least 1 of the 4 items on the Pittsburgh Agitation Scale (PAS).
* Patients who read, understand and provide written informed consent, or who have a Legally Authorized Representative (LAR).
* Patients who are in good general health.

Exclusion Criteria

* For Part B: Patients with dementia associated with Parkinson's disease and/or Lewy Body Disease, if etiology of dementia is known.
* Patients with agitation caused by acute intoxication.
* Patients treated within 4 hours prior to study drug administration with benzodiazepines, other sedatives, hypnotics or oral or short-acting intramuscular antipsychotics must be excluded.
* Treatment with alpha-1 noradrenergic blockers, alpha adrenergic antagonists within 8 hours prior to dosing.
* No new chronic medications initiated in the past 14 days prior to screening excluding over-the-counter products taken sporadically.
* Patients at significant risk of harm to themselves or others
* Patients considered medically unstable or in recovery
* Patients with history of clinically significant syncope or syncopal attacks, orthostatic hypotension within the past 2 years, current evidence of hypovolemia, orthostatic hypotension.
* Cohort 3 only: Patients who are taking nitrates or beta blockers shall be excluded. Any other anti-hypertensives should be maintained in the course of the study.
* Patients who have received an investigational drug within 30 days prior to the current agitation episode must be excluded.
* Patients experiencing clinically significant pain, per Investigator.
* Cohort 3 only: Patients who are a high fall risk assessed via the Johns Hopkins Fall Risk Assessment (total score \>13) or during the 1-week safety observation period
* Pregnancy

Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No